Scientific Program

Conference Series Ltd invites all the participants across the globe to attend 16th Global Annual Oncologists Meeting Dubai, UAE.

Day 1 :

Keynote Forum

Diana Anderson

University of Bradford, UK

Keynote: An empirical assay for assessing genomic sensitivity and for improving cancer diagnostics

Time : 09:05-09:35

OMICS International Oncologists 2017 International Conference Keynote Speaker Diana Anderson  photo
Biography:

Diana Anderson holds the Established Chair in Biomedical Sciences at the University of Bradford. She obtained her first degree in the University of Wales and second degree in the Faculty of Medicine, University of Manchester. She has 450+ peer-reviewed papers, 8 books, has successfully supervised 26 PhDs and has been a Member of Editorial Boards of 10 international journals. She has been an Editor in Chief of a book Series on Toxicology for J Wiley and Sons and the Royal Society of Chemistry respectively. She gives key note addresses at various international meetings. She is a Consultant for many international organizations, such as the WHO, NATO, TWAS, UNIDO and the OECD.

Abstract:

Detection tests have been developed for many cancers, but there is no single test to identify cancer in general. We have developed such an assay. In this modified patented Comet assay, we investigated peripheral lymphocytes of 208 individuals: 20 melanoma, 34 colon cancer, 4 lung cancer patients 18 suspect melanoma, 28 polyposis, 10 COPD patients and 94 healthy volunteers. The natural logarithm of the Olive tail moment was plotted for exposure to UVA through different agar depths for each of the above groups and analyzed using a repeated measures regression model. Response patterns for cancer patients formed a plateau after treating with UVA where intensity varied with different agar depths. In comparison, response patterns for healthy individuals returned towards control values and for pre/suspected cancers were intermediate with less of a plateau. All cancers tested exhibited comparable responses. Analyses of receiver operating characteristic curves of mean log olive tail moments, for all cancers plus pre/suspected-cancer versus controls gave a value for the area under the curve of 0.87; for cancer versus pre/suspected-cancer plus controls the value was 0.89 and for cancer alone versus controls alone (excluding pre/suspected-cancer), the value was 0.93. By varying the threshold for test positivity, its sensitivity or specificity can approach 100% whilst maintaining acceptable complementary measures. Evidence presented indicates that this modified assay shows promise as both a stand-alone test and as a possible adjunct to other investigative procedures, as part of detection programs for a range of cancers.

OMICS International Oncologists 2017 International Conference Keynote Speaker Alvaro Macieira- Coelho photo
Biography:

Alvaro Macieira-Coelho is a Research Director at the French National Institute of Health. He has received an MD from University of Lisbon, Portugal and a PhD from the University of Uppsala Sweden. He has obtained an internship at the University Hospital in Lisbon and was a Research Associate at the Wistar Institute in Philadelphia (USA) and at the Department of Cell Biology of the University of Uppsala (Sweden). He became Head of the Department of Cell Pathology at the Cancer Institute in Villejuif (France) and was a Visiting Professor at the University of Linkoping (Sweden). He has published 150 papers in professional journals and 9 books on cancer and aging. He has received many awards and honors.

Abstract:

Most of the scientific literature reports that aging favors the development of cancers. Each type of cancer, however, initiates and evolves differently and their natural history can start way back at earlier ages before their clinical manifestations. The incidence of cancers is spread through the human life span; it is the result of pre- and post-natal aggressions, individual susceptibility, and developmental changes that evolve continuously from the beginning to the end. Finally during human senescence the incidence declines for all cancers. Frequently the progression of cancers is also slower in the old. There are several possible explanations for this decline. It is time to ask why some tumors are characteristic of the young, others of maturity, others of the time of the decline of the reproductive period, and finally why the incidence of cancers declines late during senescence of the human organism. These questions should be answered before the origin of cancers can be understood.

OMICS International Oncologists 2017 International Conference Keynote Speaker Alok De photo
Biography:

Alok De has received his PhD from University of Calcutta, India. He is a Research Biologist at VA Medical Center, Kansas City, USA. His research focuses on how to use extract of Emblica officinalis as an alternative or adjunct therapeutic agent in helping to fight ovarian cancer. He has published more than 46 papers in reputed journals and more than 75 abstracts. He has been serving as a Reviewer for many journals and as an Editorial Board Member of Cancer Cell and Microenvironment and co-chair of scientific conferences.

 

Abstract:

Ovarian cancer (OC), the most lethal gynecologic cancer, may be treated with surgery, chemotherapy and/or radiation therapy. None of these strategies are very effective. Recently, we have demonstrated that Emblica officinalis (Amla) extract (AE) has anti-neoplastic effect on OC cells in vitro and in mouse xenograft tumors. We hypothesized that anti-proliferative, anti-angiogenic and anti-metastatic effect of AE on OC cells via microRNA regulated and autophagy mechanism. The effects of AE on OC cells - OVCAR3, SKOV3, A2780cis and OC cells-derived mouse xenograft tumors were studied. The effect of AE on OC cells proliferation, migration and invasion was studied. Expression of - proangiogenic receptor- IGF1R, angiogenic marker- CD31, angiogenesis regulatory transcription factor- HIF-1α, metastasis-associated transcription factor- SNAIL1, adhesion protein- E-cadherin and autophagy proteins- beclin1 and LC3B-II in OC cells and mouse xenograft tumors were studied. Expression of microRNAs in OC cells and exosomes released from OC cells after AE treatment was studied. AE dose and time dependently inhibited cell proliferation, migration and invasiveness in OC cells. AE significantly reduced the expression of HIF-1α, IG1R, CD31and proliferating marker- Ki67 both in vitro and in vivo. AE reduced SNAIL1 and induced E-cadherin expression both in vitro and in vivo.  AE significantly increased beclin1 and LC3B-II expression both in vitro and in vivo. AE significantly increased microRNA-375 expression in OC cells and in exosomes derived from OC cells. These studies suggest that AE inhibits OC cells growth via simultaneous activation of autophagy and miR-375, by targeting IGF1R, SNAIL1, down-regulating HIF-1α and inhibiting angiogenesis.

Keynote Forum

Mohammad A Qasaimeh

New York University Abu Dhabi, UAE

Keynote: Microfluidic platforms for isolating tumor cells from blood samples

Time : 10:35-11:05

OMICS International Oncologists 2017 International Conference Keynote Speaker Mohammad A Qasaimeh  photo
Biography:

Mohammad A Qasaimeh is an Assistant Professor of Mechanical and Biomedical Engineering at NYU Abu Dhabi (NYUAD), and the Tandon School of Engineering, New York University, Brooklyn, USA. His current research interests include developing microfluidic devices for clinical applications and point of care diagnostics. Prior to joining NYUAD, he was a Post-doctoral Associate at Massachusetts Institute of Technology and Harvard Medical School. He completed his PhD degree in Biomedical Engineering from McGill University, and his research has been published in several journals including Nature Communications, Lab on a Chip, and Scientific Reports. He delivered more than 15 keynotes and invited speeches at national/international conferences, and is involved in organizing several local/international conferences.

Abstract:

Over the last decade, there has been great interest in utilizing the peripheral blood circulating tumor cells (CTCs) to predict response to therapy and overall survival of cancer patients. CTCs shed from the tumor are thought to contribute to the hematogenous spread of cancer to distant sites. Despite the clinical importance of CTCs, current knowledge of these cells is extremely poor, largely owing to the fact that their isolation and enumeration is very challenging. CTCs are very rare, typically ranging from 1 to 10 cells per milliliter of blood. One important advantage of using a CTC blood test is that it possesses a significantly lower risk to the patient compared to surgically obtaining a fresh tissue biopsy. Recently, several groups started developing microfluidic platforms for CTCs isolation. Microfluidics, first introduced two decades ago, presents an attractive approach for engineering and miniaturizing bioassays by accurately controlling biological samples and their microenvironments. Microfluidics has the potential to achieve high throughputs, sensitivity and selectivity for innovative single cell analysis platforms. This talk will highlight our efforts in developing a microfluidic device for isolating plasma CTCs from multiple myeloma (MM) blood samples. MM is a cancer caused by malignant plasma cells in bone marrow. The device was able to detect a low (<10 cell/mL) level of plasma cells in normal blood, which increased significantly in MM patients. The device showed superior sensitivity and was able to detect an elevated CTCs count in MM patients that have otherwise normal peripheral blood indicators of MM.

 

Keynote Forum

Sadir Alrawi

Alzahra Cancer Center, Dubai

Keynote: Updates of HIPEC in colorectal carcinomatosis: Principals and review

Time : 11:20-11:45

OMICS International Oncologists 2017 International Conference Keynote Speaker Sadir Alrawi  photo
Biography:

Sadir Alrawi is currently the Director of all Surgical Oncology Services at Alzahra Cancer Center in the heart of Dubai and its tertiary referral cancer center for all UAE, hosting highly specialized surgical oncology subspecialties, including Colorectal, Breast Oncology, Head & Neck Surgery, Urology, Gynecological Oncology, Sarcoma/Melanoma and Peritoneal Surface Malignancy, in addition to Pancreatic and Hepatic Surgery. He is currently working as a Professor at John Hopkins medical system. He served as the Chief of Surgical Oncology Division at Tawam Hospital and was Interim Chair of Department of Surgery from October 2013-September 2015. His major interest is in Gastrointestinal Oncology, including esophageal, gastric, pancreas, liver and colonic surgery with special interest in endocrine surgery including thyroid, parathyroid and adrenal surgery.

 

Abstract:

Colorectal growth patients with peritoneal metastases (PM) are generally accepted to have poor guess, which shows it is of no incentive to receive surgical treatment and that idea was old. With the progression of surgical methods, hyperthermic intraperitoneal, chemotherapy (HIPEC) and with various modalities of chemotherapy imbuement multidisciplinary treatment as of late, the comprehension and treatment systems of colorectal peritoneal metastases (CPM) have changed drastically. As far as forecast, CPM under the palliative systemic treatment demonstrates a substandard result contrasted and nonperitoneal metastasis. By and by, some CPM patients managable to the total peritoneal cytoreductive surgery (CRS) joined with HIPEC may accomplish long haul survival. The prognostic components of CPM contain peritoneal carcinomatosis file (PCI), culmination of cytoreduction score (CC score), the nearness of extraperitoneal metastasis (liver, and so forth.), peritoneal surface illness seriousness score (PSDSS) and Japanese peritoneal arranging. Taken together, writing information propose that a multimodality approach consolidating complete peritoneal CRS in addition to HIPEC, systemic chemotherapy, and focused on treatment might be the best treatment alternative for PM from colorectal growth. We are attempting to show the significance of HIPEC in colorectal malignancy and different tumors.

Keynote Forum

Ali Al Dameh

Alzahra Cancer Center, Dubai

Keynote: Cancer treatment in the 20th century: Are we close to a cure?

Time : 11:45-12:10

OMICS International Oncologists 2017 International Conference Keynote Speaker Ali Al Dameh  photo
Biography:

Ali Aldameh is Certified in Surgery, Thoracic Oncology and Thoracic Surgery. He received his Advanced Thoracic Surgical Education in Harvard Medical School, Boston USA at Brigham and Women's Hospital. Following that, he completed an advanced fellowship in Minimally Invasive Thoracic and Foregut Surgery at Harvard Medical School. He was mentored by US leaders in their field of Thoracic Surgery who followed the tradition of pioneers in their fields, including Dr. Pearson in Toronto, Luketich in Pittsburgh, Orringer. He has closely worked with Dr. Sugarbaker the late President of the American Association of Thoracic Surgery, Dr. Scott Swanson a World Leader in VATS Surgery and Dr. Steve Menzer, an expert in Lung Surgery and Esophagectomy in North America.

Abstract:

The growth in our knowledge of Cancer Biology has led to remarkable progress in cancer prevention, early detection, and treatment. Scientists have learned more about cancer in the last 2 decades than had been learned in all the centuries preceding. This doesn’t change the fact, however, that all scientific knowledge is based on the knowledge already acquired by the hard work and discovery of our predecessors – and we know that there’s still a lot more to learn. The presentation will highlight the latest on cancer research and treatment that is advancing on so many fronts in reference to immunotherapy, targeted therapy and minimally invasive surgical solutions.